This increase in IL-6 upon TEL treatment was unexpected, given that other investigators have demonstrated reduced IL-6 plasma levels in response to ARBs in cells (Skurk et al., 2004; Iwashita et al., 2012) and in humans or animals suffering from cardiovascular or metabolic diseases (Schieffer et al., 2004; Toblli et al., 2008), thus suggesting anti-inflammatory effects under ARBs. Here, IL6 is linked to Other metabolic disease.